A practical reference on nitric oxide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-22 and is reviewed periodically as new material appears.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
| Property | Value | Notes |
|---|---|---|
| Typical storage | Minus 20 C or below | Lyophilized powder, protected from light |
| Solubility class | Freely soluble in water | Also dissolves in normal saline |
| Identity method | Mass spectrometry | Measured mass compared with calculated value |
| Purity method | Reverse-phase HPLC | Reported as area percentage of main peak |
| Common counterion | Acetate | Salt form varies by supplier and batch |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
==== 17 April 2012 massacre ==== Dismembered remains of 14 men were found in several plastic bags inside a Chrysler Voyager in the border city of Nuevo Laredo, Tamaulipas, on 17 April 2012. All of those killed were between the ages of 30 and 35. Officials stated that they found a "message signed by a criminal group", but they did not release the content of the note, nor if those killed were members of Los Zetas or of the Gulf Cartel. CNN en Español stated that the message left behind by the criminal group said that they were going to "clean up Nuevo Laredo" by killing Zeta members. The Monitor newspaper, however, said that a source outside of law enforcement but with direct knowledge of the attacks stated the 14 bodies belonged to members of Los Zetas who had been killed by the CJNG, now a branch of the Sinaloa Cartel. Following the attacks, the Sinaloa cartel's kingpin, Joaquín Guzmán Loera—better known as El Chapo Guzmán—sent a message to Los Zetas that they will fight for the control of the Nuevo Laredo plaza. The message read the following:
=== Oxidation === Plasma processing, corona treatment, and flame treatment can all be classified as surface oxidation mechanisms. These methods all involve cleavage of polymer chains in the material and the incorporation of carbonyl, and hydroxyl functional groups. The incorporation of oxygen into the surface creates a higher surface energy allowing the substrate to be coated.
== Deficiency == Plasma vitamin C is the most widely applied test for vitamin C status. Adequate levels are defined as near 50 μmol/L. Hypovitaminosis of vitamin C is defined as less than 23 μmol/L, and deficiency as less than 11.4 μmol/L. For people 20 years of age or above, data from the US 2017–18 National Health and Nutrition Examination Survey showed mean serum concentrations of 53.4 μmol/L. Deficiency was reported in 5.9% of people. Globally, vitamin C deficiency is common in low and middle-income countries, and not uncommon in high income countries. In the latter, prevalence is higher in males than in females. Plasma levels are considered saturated at about 65 μmol/L, achieved by intakes of 100 to 200 mg/day, which are well above the recommended intakes. Even higher oral intake does not further raise plasma nor tissue concentrations because absorption efficiency decreases and any excess that is absorbed is excreted in urine.
==== Metabolism ==== Doxepin is extensively metabolized by the liver via oxidation and N-demethylation. Its metabolism is highly stereoselective. Based on in vitro research, the major enzymes involved in the metabolism of doxepin are the cytochrome P450 enzymes CYP2D6 and CYP2C19, with CYP1A2, CYP2C9, and CYP3A4 also involved to a lesser extent. The major active metabolite of doxepin, nordoxepin, is formed mainly by CYP2C19 (>50% contribution), while CYP1A2 and CYP2C9 are involved to a lesser extent, and CYP2D6 and CYP3A4 are not involved. Both doxepin and nordoxepin are hydroxylated mainly by CYP2D6, and both doxepin and nordoxepin are also transformed into glucuronide conjugates. The elimination half-life of doxepin is about 15–18 hours, whereas that of nordoxepin is around 28–31 hours. Up to 10% of Caucasian individuals show substantially reduced metabolism of doxepin that can result in up to 8-fold elevated plasma concentrations of the drug compared to normal. Nordoxepin is a mixture of (E) and (Z) stereoisomers similarly to doxepin. Whereas pharmaceutical doxepin is supplied in an approximate 85:15 ratio mixture of (E)- and (Z)-stereoisomers and plasma concentrations of doxepin remain roughly the same as this ratio with treatment, plasma levels of the (E)- and (Z)-stereoisomers of nordoxepin, due to stereoselective metabolism of doxepin by cytochrome P450 enzymes, are approximately 1:1.
Sources: en.wikipedia.org
When Inside Soap's Sarah Ellis asked Weir why Mac is so attracted to Tane when Ari is "the sensible brother, who would undoubtedly give Mackenzie a secure future and everything she needs", Weir replied that it was a case of what her character is normally attracted to versus what she actually needs. When a jealous Mac fights with Tane's love interest Amber Simmons (Maddy Jevic), she knows that it will likely get back to Ari, so she tells him how she feels about his brother. Weir described her character as "very moral" and stressed that she would never cheat on Ari, but when he started to pick up on the tension between her and Tane, she knows that she cannot lie to him. Weir also said that the whole incident makes Mac realise that she does have serious feelings for Ari. Mac eventually tells Ari that she wants more than a casual relationship and if he cannot give her more commitment, then she will walk away. Ari realises that he has not given his relationship with Mac a fair chance, so he takes her out on a fishing date. Ari opens up to Mac and tells her that he has "lost his way" when it comes to romance since his time in prison, but he hopes the date will teach her more about him. Kipa-Williams said "It was a life that landed him in prison for something he regrets dearly. He doesn't want to make any mistakes again." Mac admits to Ari that she used to go fishing as a child, making their trip "the perfect date" and the pair start afresh as a proper couple. In an interview with Daniel Kilkelly of Digital Spy, Weir believed Ari was "the best match" for Mac.
From June 2023 to April 2024, Serbian television presenter Bojana Janković (née Nikolić), known for hosting the show City, posted to the internet forum Bluelight that she was bedridden with symptoms consistent with neuroleptic-induced deficit syndrome after receiving six depot injections of paliperidone palmitate (four shots of Invega Sustenna and two shots of Invega Trinza). She wrote: "My main problem is 0 motivation, low energy and anhedonia. Also i have cognitive issues. Beddriden mostly..." The injections were prescribed by her private psychiatrist and friend around the time of her divorce from Ognjen Janković, a member of the hip-hop group Beogradski Sindikat. She died by suicide in Belgrade on April 19, 2024, aged 46.
In July 2024, Lyme Disease Vaccine Reached Completion of the Primary Series In July 2024, Pfizer and Flagship Pioneering announced an "Innovation Supply Chain" partnership to co-develop 10 drug candidates. Each party committed $50 million upfront, leveraging Flagship's ecosystem of over 40 startups to align with Pfizer's priorities. Pfizer will fund the selected programs and has the option to license or acquire assets, with potential success milestones and royalties reaching up to $700 million per commercialized drug. Two programs, focused on obesity and cardiovascular diseases, have already been initiated. In July 2024, Pfizer advanced its obesity treatment research through the development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist: In August 2024, Pfizer introduced PfizerForAll, a digital platform designed to streamline access to healthcare and wellness resources in the United States. In October 2024, Pfizer announced positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC. In October 2024, Pfizer announced a partnership with the Ignition AI Accelerator, a collaborative initiative by Nvidia, Tribe, and Digital Industry Singapore (DISG). The collaboration aims using artificial intelligence to expedite drug discovery and development processes, improve operational efficiency, and streamline stakeholder engagement. The initiative also focuses on optimizing manufacturing processes, including improving yields and reducing cycle times.
== Plays == Vera; or, The Nihilists (1880/1882) (text) The Duchess of Padua (1883) (text) Lady Windermere's Fan (1892) (text) A Woman of No Importance (1893) (text) An Ideal Husband (1895) (text) The Importance of Being Earnest (1895) (text) Salomé (1896) Translated from French by Lord Alfred Douglas (text) La Sainte Courtisane (Incomplete) (text) A Florentine Tragedy (Incomplete) (text) (Dates are dates of first performance, which approximate better to the probable date of composition than dates of publication.)
Alexander first came to Yugoslavia in 1991. He actively worked with the opposition to Slobodan Milošević and moved to Yugoslavia after Milošević had been deposed in 2000. On 27 February 2001, the parliament of the Federal Republic of Yugoslavia (FRY) passed legislation conferring citizenship on members of the Karađorđević family. The legislation may also have effectively annulled a decree stripping the family of its citizenship of the Socialist Federal Republic of Yugoslavia (SFRY) in 1947. The annulment was the topic of some debate. Notably, the FRY was not the successor of the SFRY; rather the FRY was a new state (and was admitted to the United Nations as a new state on that basis). Therefore, the jurisdiction of a new state to annul an action of a different former state was questioned. In effect, the Karađorđević family had FRY citizenship conferred upon them, not "restored" as such. The FRY legislation also addresses restoration of property to the Karađorđević family. In March 2001, the property seized from his family, including royal palaces, was returned for residential purposes with property ownership to be decided by parliament at some later date. He has lived since 17 July 2001 in the Royal Palace (Kraljevski Dvor) in Dedinje, an exclusive area of Belgrade. The Palace, which was completed in 1929, is one of two royal residences in the Royal Compound; the other is the White Palace, which was completed in 1936.
Sources: en.wikipedia.org
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.
Cold storage at minus twenty degrees Celsius or below is the common recommendation for the lyophilized powder, together with protection from light and moisture. Dissolved material is generally treated as less stable and is handled cold with short working windows.
A useful certificate lists the analytical method used, the measured purity, the mass determined by spectrometry, and the storage conditions. Independent verification from a second laboratory is sometimes requested, since supplier-issued documents are not always produced in the same facility as the material.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.